​

BridgeBio Pharma Ownership | Who Owns BridgeBio Pharma?

OverviewForecastRevenueFinancialsChartTranscripts

BridgeBio Pharma Ownership Summary

BridgeBio Pharma is owned by 97.37% institutional investors, 4.93% insiders. Kohlberg kravis roberts is the largest institutional shareholder, holding 13.40% of BBIO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.91% of its assets in BridgeBio Pharma shares.

BBIO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBridgeBio Pharma97.37%4.93%-2.30%
SectorHealthcare Stocks 279.42%10.64%-190.05%
IndustryBiotech Stocks 64.05%10.69%25.27%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Kohlberg kravis roberts25.26M13.40%$693.16M
Viking global investors lp25.12M13.33%$689.32M
Vanguard group15.08M8.00%$413.74M
Blackrock funding, inc. /de13.71M7.27%$376.19M
Blackrock12.45M6.64%$315.31M
State street6.18M3.28%$169.65M
Aisling capital management lp6.07M3.22%$166.51M
Janus henderson group4.91M2.60%$134.67M
Farallon capital management4.20M2.23%$115.11M
Laurion capital management lp3.74M1.98%$102.65M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Aisling capital management lp6.07M59.08%$166.51M
Kohlberg kravis roberts25.26M18.56%$693.16M
Prosight management, lp995.00K7.55%$27.30M
Cutter capital management, lp560.34K6.30%$15.38M
Superstring capital management lp262.14K6.23%$7.19M
Lion point capital, lp40.30K5.79%$1.11M
Exome asset management246.70K5.09%$6.77M
Sphera funds management905.28K4.49%$24.84M
Frazier life sciences management3.63M4.30%$92.01M
Adar1 capital management678.86K3.72%$18.63M

Top Buyers

HolderShares% AssetsChange
Farallon capital management4.20M0.58%2.45M
Blackrock12.45M0.01%1.98M
Woodline partners lp2.21M0.41%1.26M
Norges bank1.07M0.00%1.07M
Capital research global investors3.53M0.02%912.44K

Top Sellers

HolderShares% AssetsChange
Lord, abbett---2.80M
Perceptive advisors---1.22M
Paradigm biocapital advisors lp---1.09M
Hhlr advisors---1.02M
Pictet asset management sa1.81M0.05%-995.59K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.07M0.00%1.07M$29.24M
Deep track capital, lp819.16K0.84%819.16K$22.48M
Pfm health sciences, lp290.24K0.49%290.24K$7.96M
Susquehanna fundamental investments238.00K0.09%238.00K$6.53M
Balyasny asset management207.28K0.01%207.28K$5.25M

Sold Out

HolderChange
Creekmur asset management-3.00
Financial gravity asset management-3.00
Pfg private wealth management-11.00
Creative financial designs inc /adv-16.00
Global financial private client-20.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202534412.05%185,144,5074.79%971.11%19624.05%825.13%
Dec 31, 20243048.57%172,882,4320.83%911.11%1556.90%781.30%
Sep 30, 2024278-2.11%171,231,529-1.98%901.05%147-3.29%742.78%
Jun 30, 20242841.43%174,683,4282.52%931.02%15211.76%72-15.29%
Mar 31, 20242803.32%170,388,9093.05%950.92%136-5.56%858.97%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv5.53M2.91%661.50K
Vanguard US Total Market Shares ETF4.53M2.38%3.92K
Vanguard Small Cap Index4.18M2.20%338.16K
iShares Russell 2000 ETF3.75M1.98%-60.70K
SPDR® S&P Biotech ETF2.39M1.26%58.91K
Vanguard Small Cap Growth Index Inv2.34M1.23%228.31K
Vanguard Institutional Extnd Mkt Idx Tr2.29M1.20%-7.52K
American Funds SMALLCAP World A2.07M1.09%-596.87K
Macquarie Small Cap Core I1.68M0.88%1.06M
Janus Henderson Global Life Sciences1.62M0.85%573.25K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 01, 2025Kumar Neil Chief Executive OfficerSell$782.09K
Jul 02, 2025Kumar Neil Chief Executive OfficerSell$854.54K
Jul 01, 2025Kumar Neil Chief Executive OfficerSell$72.90K
Jul 01, 2025Kumar Neil Chief Executive OfficerSell$777.78K
Jul 01, 2025Kumar Neil Chief Executive OfficerSell$68.63K

Insider Transactions Trends

DateBuySell
2025 Q3-6
2025 Q2-16
2025 Q1-15
2024 Q4-3
2024 Q3-5

BBIO Ownership FAQ

Who Owns BridgeBio Pharma?

BridgeBio Pharma shareholders are primarily institutional investors at 97.37%, followed by 4.93% insiders and -2.30% retail investors. The average institutional ownership in BridgeBio Pharma's industry, Biotech Stocks , is 64.05%, which BridgeBio Pharma exceeds.

Who owns the most shares of BridgeBio Pharma?

BridgeBio Pharma’s largest shareholders are Kohlberg kravis roberts (25.26M shares, 13.40%), Viking global investors lp (25.12M shares, 13.33%), and Vanguard group (15.08M shares, 8.00%). Together, they hold 34.72% of BridgeBio Pharma’s total shares outstanding.

Does Blackrock own BridgeBio Pharma?

Yes, BlackRock owns 6.64% of BridgeBio Pharma, totaling 12.45M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 315.31M$. In the last quarter, BlackRock increased its holdings by 1.98M shares, a 18.93% change.

Who is BridgeBio Pharma’s biggest shareholder by percentage of total assets invested?

Aisling capital management lp is BridgeBio Pharma’s biggest shareholder by percentage of total assets invested, with 59.08% of its assets in 6.07M BridgeBio Pharma shares, valued at 166.51M$.

Who is the top mutual fund holder of BridgeBio Pharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of BridgeBio Pharma shares, with 2.91% of its total shares outstanding invested in 5.53M BridgeBio Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools